Kura Oncology to Report Third Quarter 2025 Financial Results

Core Insights - Kura Oncology, Inc. will report its third quarter 2025 financial results on November 4, 2025, before U.S. markets open [1] - A conference call and webcast will be held at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update [1] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment [3] - The company's pipeline includes small molecule drug candidates targeting cancer signaling pathways, specifically for hematologic malignancies and solid tumors [3] - Kura is developing ziftomenib, a menin inhibitor aimed at specific genetic drivers of acute myeloid leukemias, and is advancing menin inhibition for acute leukemias and solid tumors [3]